Amicus Therapeutics Reaches Profitability Milestone in Q3

Amicus Therapeutics has achieved a significant financial turning point, reporting its first GAAP-profitability alongside substantial revenue growth. The biotechnology firm’s third-quarter performance exceeded market expectations, signaling a potential new chapter for the specialized pharmaceutical company.

The company’s quarterly results revealed impressive financial health, with revenue climbing nearly 20% compared to the same period last year. Most notably, Amicus recorded its first GAAP net income of $17.3 million. The adjusted earnings per share reached $0.17, surpassing analyst forecasts by a solid $0.05.

This positive financial development is supported by a strengthened balance sheet, with cash and equivalents now standing at $263.8 million. The company’s flagship treatments continue to demonstrate strong market performance, driving Read more...